Aratana down 27% as Stifel softens view

|About: Aratana Therapeutics (PETX)|By:, SA News Editor

Aratana Therapeutics (PETX -26.9%) is down on 70% higher volume in early trade on the heels of a downgrade to Hold at Stifel. Analyst Jonathan Block also trimmed his price by 38% to $5 citing a thin pipeline and little progress on extending the duration of canine appetite stimulant Entyce (capromorelin oral solution).

Subscribe for full text news in your inbox